Audiologists in Berkeley Heights, NJ Accepting Medicare

6 Audiologists found. Showing 1 - 6

Jacklyn Penny Churchill, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-273-4300

Dr. Jordana Moesch-friedman, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8868

Randi Rachael Pogash, MS, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-273-4300

Dr. Caitlin Faccone, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8992

Dr. Jennifer Marianne Marchitto, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8868

Dr. Kayla Holstad, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1 Diamond Hill Rd, Berkeley Heights, NJ 07922 Phone: 908-277-8868

News Archive

U.N.-backed meeting in Bangkok will examine how legal barriers in Asia hamper fight against HIV/AIDS

"Legal barriers are obstructing the fight against HIV/AIDS in the Asia, where 19 nations outlaw same-sex relations and 29 countries criminalize prostitution, United Nations experts said Wednesday," on the eve of the Global Commission of HIV and the Law meeting in Bangkok, Deutsche Presse-Agentur/M&C reports.

Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line

Sunshine Biopharma Inc., a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.

NIH study identifies distinct mechanisms of long-term HIV control in two people after treatment disruption

Research led by scientists at the National Institutes of Health has identified two distinct ways that people with HIV can control the virus for an extended period after stopping antiretroviral therapy (ART) under medical supervision.

New discovery could enable scientists to fine-tune activity of cancer-killing immune cells

A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects.

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS (peginesatide) Injection.

Read more Medical News

› Verified 5 days ago